Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 8.11: Therapie der akuten myeloischen Leukämie im höheren Lebensalter

Autor/en: U. Schuler, A. Reichle
Letzte Änderung: 07.10.2008
  • Agha ME et al.
    Single Agent Gemtuzumab Ozogamycin (Mylotarg) Is Effective in Inducing Hematologic Remission in Elderly Patients with Normal Cytogenetics.
    ASH Annual Meeting Abstracts 2004;104:4402.

  • Agura E et al.
    Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.
    ASH Annual Meeting Abstracts 2006;108:1951.

  • Amadori S et al.
    Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study.
    ASH Annual Meeting Abstracts 2004;104:877.

  • Amadori S et al.
    Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
    Blood 2005;106:27-34.

  • Anderson JE et al.
    Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
    Blood 2002;100:3869-3876.

  • Bacher U et al.
    Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
    Haematologica 2005;90:1502-1510.

  • Baer MR et al.
    Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients >/= 60 Years in First Complete Remission (CALGB 9720).
    ASH Annual Meeting Abstracts 2006;108:424.

  • Becker C et al.
    High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.
    Blood 2004;ASH-abstracts 800.

  • Bertz H, Potthoff K, Finke J.
    Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    J Clin Oncol 2003;21:1480-1484.

  • Brune M et al.
    Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
    Blood 2006;108:88-96.

  • Buchner T et al.
    6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    J Clin Oncol 2003;21(24):4496-4504.

  • Buchner T et al.
    Treatment of older patients with AML.
    Crit Rev Oncol Hematol 2005;56:247-259.

  • Buchner T et al.
    Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
    J Clin Oncol 2006;24:2480-2489.

  • Burnett AK et al.
    A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
    Cancer 2007;109(6):1114-1124.

  • Burnett AK et al.
    Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.
    ASH Annual Meeting Abstracts 2006a;108:1985.

  • Burnett AK et al.
    The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.
    ASH Annual Meeting Abstracts 2006b;108:13.

  • Cripe LD et al.
    A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS): ECOG 3999.
    ASH Annual Meeting Abstracts 2006;108:423.

  • Etienne A et al.
    Impact of Comorbidities on the Outcome of Elderly Patients with Acute Myeloid Leukemia.
    ASH Annual Meeting Abstracts 2006;108:1976.

  • Garcia-Suarez J et al.
    Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy.
    Br J Haematol 2003;120:209-216.

  • Giles F et al.
    Comorbidity Scoring Using the Hematopoetic Cell Transplantation Comorbidity Index (HCTCI) Is Predictive of Early Death Rate and Event Free Survival (EFS) in Patients over 60 Years of Age Receiving Induction Therapy for Acute Myeloid Leukemia (AML).
    ASH Annual Meeting Abstracts 2006;108:1975.

  • Godwin JE et al.
    A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
    Blood 1998;91:3607-3615.

  • Goldstone AH et al.
    Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
    Blood 2001;98:1302-1311.

  • Eom KS et al.
    Gemtuzumab Ozogamicin in Combination with Attenuated Dose of Standard Induction Chemotherapy Therapy Can Successfully Induce Complete Remission without Increasing Toxicity in Patients with Newly Diagnosed Acute Myeloid Leukemia Aged 55 or Older.
    ASH Annual Meeting Abstracts 2006;108:1982.

  • Haferlach T et al.
    Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    J Clin Oncol 2003;21:256-265.

  • Hegenbart U et al.
    Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
    J Clin Oncol 2006;24:444-453.

  • Heil G et al.
    Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia.
    Leukemia 2006;20:404-409.

  • Juliusson G et al.
    Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
    Leukemia 2006;20(1):42-47.

  • Kujawski LA et al.
    Gemtuzumab Ozogamicin (MylotargR) as Primary Induction Therapy for Elderly Patients with Acute Myeloid Leukemia: A Phase II Trial.
    ASH Annual Meeting Abstracts 2004;104:4508.

  • Kujawski LA et al.
    Combination of Daunorubicin and Cytarabine Chemotherapy with Gemtuzumab Ozogamicin as Initial Therapy for Elderly Patients with Previously Untreated Acute Myeloid Leukemia.
    ASH Annual Meeting Abstracts 2005;106:4636.

  • Lang K et al.
    Trends in the treatment of acute myeloid leukaemia in the elderly.
    Drugs Aging 2005;22:943-955.

  • Latagliata R et al.
    Conservative treatment for patients over 80 years with acute myelogenous leukemia.
    Am J Hematol 2002;71:256-259.

  • Latagliata R et al.
    Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).
    ASH Annual Meeting Abstracts 2006;108:1979.

  • Leith CP et al.
    Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
    Blood 1999;94:1086-1099.

  • Lowenberg B et al.
    On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
    J Clin Oncol 1989;7:1268-1274.

  • Mayer RJ et al.
    Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
    N Engl J Med 1994;331:896-903.

  • Nand S et al.
    Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.
    ASH Annual Meeting Abstracts 2006;108:1981.

  • Norgaard M et al.
    Short-term mortality of bacteraemia in elderly patients with haematological malignancies.
    Br J Haematol 2006;132:25-31.

  • Phekoo KJ et al.
    The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
    Haematologica 2006;91:1400-1404.

  • Pirrotta MT et al.
    Phase II Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen as Induction Therapy Plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients.
    ASH Annual Meeting Abstracts 2005;106:4613.

  • Pulsoni A, Latagliata R, Pagano L.
    Management of elderly patients with acute myeloid leukemia.
    Haematologica 2004;89:ELT10.

  • Schlenk RF et al.
    Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
    Leukemia 2004;18:1798-1803.

  • Schlenk RF et al.
    All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.
    ASH Annual Meeting Abstracts 2006;108:1949.

  • Sekeres MA et al.
    A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.
    ASH Annual Meeting Abstracts 2006;108:2669.

  • Sorror ML et al.
    Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
    Blood 2005;106:2912-2919.

  • Stone RM et al.
    Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    N Engl J Med 1995;332:1671-1677.

  • van der Holt B et al.
    The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
    Blood 2005;106:2646-2654.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag" (Publikation als Buch)
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
und in Kooperation mit "Studien-Allianz Leukämie"
Deutscher Ärzte-Verlag  Studien-Allianz Leukämien
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: